Differentiated thyroid carcinoma in Denizli region: Demographic data and clinical features from a tertiary center
Abstract
Purpose: Differentiated thyroid carcinoma (DTC) is the most common endocrine malignancy, with its incidence rising worldwide. This study aimed to evaluate the demographic and clinical characteristics of patients with DTC treated at Pamukkale University and to compare them with national and international data. In addition, the study was designed as an educational initiative, offering medical students practical experience in research methodology.
Materials and methods: A total of 299 patients (246 females, 53 males) who underwent thyroidectomy and were referred for radioiodine ablation between January 2014 and December 2021 were retrospectively analyzed. Age, sex, histological subtype, tumor size, focality, lymph node involvement, distant metastasis, and administered radioiodine activity (RAI) were collected. Statistical analyses were performed using SPSS version 25.0.
Results: The mean age at diagnosis was 47.3±14.2 years (46.9 for females, 48.9 for males), with a female-to-male ratio of 4.8:1. The classical variant of papillary thyroid carcinoma was the most frequent subtype (74.4%), followed by the follicular variant (12%) and oncocytic thyroid carcinoma (OTC) (7.4%). Regional lymph node metastases were observed in 16.4% and distant metastases in 3.0% of patients. Follicular thyroid carcinoma (FTC) was associated with a higher rate of distant metastasis compared with papillary thyroid carcinoma (PTC) (10.5% vs. 3%). Regarding treatment, 72% of patients received ≤100 mCi radioiodine, while 20% received >100 mCi.
Conclusion: Female sex and papillary histopathology are predominant in DTC. Follicular thyroid carcinoma tends to exhibit a higher propensity for distant metastasis compared with papillary thyroid carcinoma. The dual purpose of this study highlights both its epidemiological contribution and its role in training medical students in applied research methodology.
Keywords
Supporting Institution
Ethical Statement
References
- Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834
- Chen DW, Lang BHH, McLeod DSA, Newbold K, Haymart MR. Thyroid cancer. Lancet. 2023;401(10387):1531-1544. doi:10.1016/S0140-6736(23)00020-X
- Pizzato M, Li M, Vignat J, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022;10(4):264-272. doi:10.1016/S2213-8587(22)00035-3
- Du B, Wang F, Wu L, et al. Cause-specific mortality after diagnosis of thyroid cancer: a large population-based study. Endocrine. 2021;72(1):179-189. doi:10.1007/s12020-020-02445-8
- Li W, Liang H, Wang W, et al. Global cancer statistics for adolescents and young adults: population based study. J Hematol Oncol. 2024;17(1):99. doi:10.1186/s13045-024-01623-9
- T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. Türkiye Kanser İstatistikleri 2018. Ankara: T.C. Sağlık Bakanlığı Yayınları; 2022.
- Karaçavuş S, Bağlayan K, Şahin S, et al. Yozgat Bölgesinde Diferansiye Tiroid Kanseri Nedeniyle Takip Edilen Hastaların Klinik ve Demografik Özellikleri. Bozok Tıp Dergisi. 2014;4(2):26-30. doi:10.16919/btd.13528
- Franssila KO, Ackerman LV, Brown CL, Hedinger CE. Follicular carcinoma. Semin Diagn Pathol. 1985;2(2):101-122.
Details
Primary Language
English
Subjects
Clinical Sciences (Other)
Journal Section
Research Article
Authors
Aziz Gültekin
*
0000-0002-0311-8077
Türkiye
Enes Akbaş
0009-0005-9124-4514
Türkiye
Furkan Ay
0009-0008-9090-5714
Türkiye
Oğuz Furkan Çelik
0009-0009-2172-7560
Türkiye
Zeynel Çandır
0009-0009-1766-4050
Türkiye
Publication Date
July 10, 2026
Submission Date
September 12, 2025
Acceptance Date
October 20, 2025
Published in Issue
Year 2026 Volume: 19 Number: 3
